Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.
Saved in:
| Title: | Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. |
|---|---|
| Authors: | Lawitz, Eric1 (AUTHOR) lawitz@txliver.com, Gane, Edward2 (AUTHOR), Feld, Jordan J.3 (AUTHOR), Buti, Maria4 (AUTHOR), Foster, Graham R.5 (AUTHOR), Rabinovitz, Mordechai6 (AUTHOR), Burnevich, Eduard7 (AUTHOR), Katchman, Helena8 (AUTHOR), Tomasiewicz, Krzysztof9 (AUTHOR), Lahser, Fred10 (AUTHOR), Jackson, Beth10 (AUTHOR), Shaughnessy, Melissa10 (AUTHOR), Klopfer, Stephanie10 (AUTHOR), Yeh, Wendy W.10 (AUTHOR), Robertson, Michael N.10 (AUTHOR), Hanna, George J.10 (AUTHOR), Barr, Eliav10 (AUTHOR), Platt, Heather L.10 (AUTHOR), Gordon, Stuart C. (AUTHOR), Lawitz, Eric J. (AUTHOR) |
| Source: | Journal of Viral Hepatitis. Sep2019, Vol. 26 Issue 9, p1127-1138. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 13520504 |
|---|---|
| DOI: | 10.1111/jvh.13132 |
